581-50-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.581-50-0,2,3′-Bipyridine,as a common compound, the synthetic route is as follows.
General procedure: Complexes 3-6 were prepared according to the following procedure:after stirring for 1 h a methanolic solution (20 mL) ofHindo (0.4 mmol, 143 mg) and KOH (0.4 mmol, 23 mg), the solutionwas added to a methanolic solution (5 mL) of NiCl26H2O(0.2 mmol, 47 mg) simultaneously with a methanolic solution(5 mL) of bipy (0.2 mmol, 31 mg) for 3, bipyam (0.2 mmol,34 mg) for 4, phen (0.2 mmol, 36 mg) for 5 and Hpko (0.4 mmol,79 mg) for 6. The resultant solution was stirred for 30 min andwas left to evaporate slowly. Light-green microcrystalline product of complex 4 (105 mg, 55%) was collected after two weeks. Anal. Calc. for [Ni(indo)2(bipyam)], 4 (C48H39Cl2N5NiO8) (MW = 943.48) C, 61.11; H, 4.17; N, 7.42 found: C, 60.98; H, 4.04; N, 7.31%. IR (KBr disk): numax, cm-1; nu(C=O)indo, 1678(vs); nuasym(CO2), 1590 (vs); nusym(CO2), 1414 (s); Deltanu(CO2) = 176 cm-1; rho(C-H)bipyam: 765 (m). UV-Vis: as Nujol mull, lambda(nm): 995 (sh), 657, 418 (sh), 324, 308 (sh); in DMSO, lambda(nm) (epsilon, M-1cm-1): 997 (sh) (20), 662 (60), 424 (sh) (230), 324 (12740), 293 (17020); 10Dq = 10030 cm-1, B = 573 cm-1, 10Dq/B = 17.5. mueff at room temperature = 3.25 BM. Soluble in CHCl3 and DMSO (LambdaM = 5 S¡¤cm2¡¤mol-1, in 1 mM DMSO solution).
581-50-0 2,3′-Bipyridine 11389, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Article; Perontsis, Spyros; Tialiou, Alexia; Hatzidimitriou, Antonios G.; Papadopoulos, Athanasios N.; Psomas, George; Polyhedron; vol. 138; (2017); p. 258 – 269;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI